MELBOURNE, Australia and PRINCETON, N.J.—Opthea Limited (ASX/NASDAQ: OP), a clinical-stage biopharmaceutical company, has announced executive leadership changes in commercial and finance, as well as senior hires for biometrics, clinical operations and market access. Daniel Geffken, co-founder and managing director at Danforth Advisors, will assume the role of chief financial officer on an ad-interim basis, reporting to Opthea CEO Frederic Guerard, PharmD, the company stated. Geffken succeeds Peter Lang, who is leaving the company for personal reasons. Additionally, Mike Campbell has been appointed chief commercial officer, also reporting to Guerard, and is succeeding Judith Robertson, who is leaving the company to pursue other opportunities. Read More